Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Immunology

Internal Medicine

Pediatrics

Infectious Diseases

Show all topics

DOI

10.1016/s0140-6736(20)32466-1

License

CC-BY-NC-ND

Other Formats

PDF